Attenuated response of myocardial flow reserve to lipid-lowering therapy with atorvastatin in patients with familial hypercholesterolemia.

被引：0
|
作者：
Ishida, Y
Tsushima, M
Fukuchi, K
Miyake, Y
Sagoh, M
Oka, H
机构：
[1] Natl Cardiovasc Ctr, Dept Radiol & Nucl Med, Suita, Osaka 565, Japan
[2] Natl Cardiovasc Ctr, Dept Cardiol, Suita, Osaka 565, Japan
来源：
JOURNAL OF NUCLEAR MEDICINE | 2003年 / 44卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
171
引用
收藏
页码：54P / 54P
页数：1
相关论文
共 50 条
  • [41] Use and persistence of lipid-lowering therapy in patients with severe hypercholesterolemia: A prospective study
    Matta, Maria G.
    Saenz, Benjamin
    Schreier, Laura
    Corral, Agustina
    Sarobe, Agustina
    Corral, Pablo
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2021, 33 (06): : 308 - 313
  • [42] Lipid-Lowering Effect of Nattokinase in Patients with Primary Hypercholesterolemia
    Wu, Der-Jinn
    Lin, Cheng-Sheng
    Lee, Ming-Yung
    ACTA CARDIOLOGICA SINICA, 2009, 25 (01) : 26 - 30
  • [43] Effect of Lipid-Lowering Therapy on Myocardial Ischemia
    Dan Tzivoni
    Jacob Klein
    Cardiovascular Drugs and Therapy, 1998, 12 : 135 - 139
  • [44] Effect of lipid-lowering therapy on myocardial ischemia
    Tzivoni, D
    Klein, J
    CARDIOVASCULAR DRUGS AND THERAPY, 1998, 12 (Suppl 1) : 135 - 139
  • [45] Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia
    Junior Lima Santos, Paulo Caleb
    Morgan, Aline Cruz
    Jannes, Cintia Elin
    Turolla, Luciana
    Krieger, Jose Eduardo
    Santos, Raul D.
    Pereira, Alexandre Costa
    ATHEROSCLEROSIS, 2014, 233 (01) : 206 - 210
  • [46] Lipoprotein(a) levels and cholesterol efflux capacity: inverse association and impact on atherosclerosis in familial hypercholesterolemia patients on lipid-lowering therapy
    Ogura, M.
    Matsuki, K.
    Kataoka, Y.
    Funabashi, S.
    Harada-Shiba, M.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [47] Flow common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    Phillips, PS
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (03): : 130 - 131
  • [48] NUMBER OF LIPID-LOWERING MEDICATIONS AND ATTAINMENT OF LIPID GOALS IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: DATA FROM THE LATVIAN REGISTRY
    Nesterovics, G.
    Saripo, V.
    Meiere, R.
    Terauda, E.
    Skudrina, G.
    Gilis, D.
    Erglis, A.
    Latkovskis, G.
    ATHEROSCLEROSIS, 2022, 355 : E176 - E176
  • [49] LIPID-LOWERING THERAPY WITH PCSK9 INHIBITORS: FAMILIAL HYPERCHOLESTEROLEMIA VS GENERAL POPULATION OUTCOMES
    Matteucci, A.
    Alonzo, A.
    Castello, L.
    Spinelli, A.
    Marino, G.
    Schiaffini, G.
    Di Fusco, S.
    Aquilani, S.
    Aiello, A.
    Colivicchi, F.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26
  • [50] THE LEVEL OF LIPOPROTEIN (A) A PREDICTOR OF SUBCLINICAL ATHEROSCLEROSIS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA WHO ARE NOT RECEIVING LIPID-LOWERING THERAPY
    Galimova, L. F.
    Sadykova, D. I.
    Slastnikova, E. S.
    Usova, N. E.
    ATHEROSCLEROSIS, 2020, 315 : E143 - E143
12345